AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28490512 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight z score at conception
Number of subjects: 670
Study 25623617 — intervention group
Group type: EXPERIMENTAL
Intervention: NEXA (neuromuscular exercise)
Number of subjects: 100
Study 25623617 — intervention group
Group type: EXPERIMENTAL
Intervention: QS (quadriceps strengthening)
Number of subjects: 100
Study 22930239 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparotomy for gynecologic cancer
Number of subjects: 181
Study 20924393 — intervention group
Group type: EXPERIMENTAL
Intervention: Granular PGX (2.5, 5, and 7.5 g) at breakfast
Number of subjects: 10
Study 20924393 — intervention group
Group type: EXPERIMENTAL
Intervention: Granular PGX (5 g) consumed from -45 to +15 min before and after a meal
Number of subjects: 10
Study 20924393 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsules containing 3, 4.5, and 6 g PGX consumed with the evening meal
Number of subjects: 10
Study 18191645 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (AT) 800 mg/day
Number of subjects: 20
Study 18191645 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-tocopherol (GT) 800 mg/day
Number of subjects: 20
Study 18191645 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of AT and GT
Number of subjects: 20
Study 18191645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16679981 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Milk (WM)
Number of subjects: 3
Study 16679981 — intervention group
Group type: COMPARATOR
Intervention: Fat-Free Milk (FM)
Number of subjects: 3
Study 16679981 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric Milk (IM)
Number of subjects: 3
Study 15283007 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus CBT
Number of subjects: 30
Study 15283007 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg modafinil plus CBT
Number of subjects: 30
Study 15283007 — intervention group
Group type: COMPARATOR
Intervention: 100 mg modafinil plus contact control (monitor‐only condition)
Number of subjects: 30
Study 11389575 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (SB), max. 2.5 mg
Number of subjects: 17
Study 11389575 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB), max. 0.5 mg
Number of subjects: 17
Study 11389575 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Salbutamol and Ipratropium bromide
Number of subjects: 17
Study 11389575 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 17
Study 9431826 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered ketoprofen (12.5 mg)
Number of subjects: 24
Study 9431826 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered ketoprofen (25 mg)
Number of subjects: 24
Study 9431826 — intervention group
Group type: COMPARATOR
Intervention: Unbuffered ketoprofen (12.5 mg)
Number of subjects: 24
Study 9431826 — intervention group
Group type: COMPARATOR
Intervention: Unbuffered ketoprofen (25 mg)
Number of subjects: 24
Study 8390644 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention with public health nursing and homemaker services for up to 8 weeks
Number of subjects: 100
Study 8390644 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention
Number of subjects: 100
Study 8390644 — intervention group
Group type: COMPARATOR
Intervention: Control group (discharged at physician's discretion)
Number of subjects: 100
Study 3566996 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 2 mg, i.v. during surgery
Number of subjects: 2
Study 3566996 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane in oxygen (1.5% end‐tidal)
Number of subjects: 2
Study 3566996 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane in 67% nitrous oxide in oxygen (0.75% end‐tidal)
Number of subjects: 2
Study 31532137 — intervention group
Group type: EXPERIMENTAL
Intervention: Thread-embedding therapy in addition to routine rehabilitation treatment (physical therapy, spleen-strengthening, kidney-nourishing, Governor Vessel-regulating massage, vibroacoustic therapy, and scalp acupuncture), applied at acupoints (LI15, SJ14, SI11, ST25, C4, L1, L4), 6-8 acupoints selected each time, once a week for 4 weeks, with 3 courses total.
Number of subjects: 70
Study 31532137 — intervention group
Group type: COMPARATOR
Intervention: Routine rehabilitation treatment (physical therapy, spleen-strengthening, kidney-nourishing, Governor Vessel-regulating massage, vibroacoustic therapy, and scalp acupuncture).
Number of subjects: 70
Study 27100318 — intervention group
Group type: EXPERIMENTAL
Intervention: Smith machine bench press
Number of subjects: 27
Study 27100318 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbell bench press
Number of subjects: 27
Study 27100318 — intervention group
Group type: EXPERIMENTAL
Intervention: Dumbbell bench press
Number of subjects: 27
Study 26467531 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon
Number of subjects: 30
Study 26467531 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 30
Study 23641817 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung Support Formula (1 capsule twice a day for 12 weeks)
Number of subjects: 100
Study 23641817 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 capsule twice a day for 12 weeks)
Number of subjects: 100
Study 21341922 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief behaviorally based smoking-cessation treatment
Number of subjects: 0
Study 21341922 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment control condition
Number of subjects: 0
Study 21341922 — intervention group
Group type: EXPERIMENTAL
Intervention: Craving
Number of subjects: 0
Study 19054718 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized telephone patient education intervention delivered 1-2 days pre-discharge
Number of subjects: 0
Study 19054718 — intervention group
Group type: COMPARATOR
Intervention: Individualized telephone patient education intervention delivered 1-2 days post-discharge
Number of subjects: 0
Study 17351510 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 100 mg/d
Number of subjects: 325
Study 17351510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study 14965835 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 24
Study 14965835 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study 11702100 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase 100 mg (5 patients)
Number of subjects: 7
Study 11702100 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin 1,750 IU/h (2 patients)
Number of subjects: 7
Study 9131360 — intervention group
Group type: EXPERIMENTAL
Intervention: Professionally led support group intervention combining group therapy techniques with psychoeducational strategies in six weekly sessions
Number of subjects: 46
Study 7964860 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous high-dose immunoglobulins
Number of subjects: 12
Study 7964860 — intervention group
Group type: COMPARATOR
Intervention: GTOE supplementation therapy
Number of subjects: 12
Study 2825505 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic-index diet
Number of subjects: 6
Study 2825505 — intervention group
Group type: COMPARATOR
Intervention: High-glycemic-index diet
Number of subjects: 6
Study 31301533 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzathine penicillin G (BPG) administered every 4 weeks
Number of subjects: 916
Study 31301533 — intervention group
Group type: COMPARATOR
Intervention: No medical intervention (Control)
Number of subjects: 916
Study 28567555 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐PROMs questionnaire (completed online on a monthly basis for 12 months)
Number of subjects: 147
Study 28567555 — intervention group
Group type: COMPARATOR
Intervention: Control group (continued care in the same style for 12 months)
Number of subjects: 147
Study 28567555 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐PROMs questionnaire
Number of subjects: 147
Study 28567555 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of flares (regardless of severity)
Number of subjects: 147
Study 26043004 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspheric IOL
Number of subjects: 40
Study 26043004 — intervention group
Group type: COMPARATOR
Intervention: Spherical IOL
Number of subjects: 40
Study 22994457 — intervention group
Group type: EXPERIMENTAL
Intervention: QuitCoach personalized tailored internet‐delivered advice program
Number of subjects: 3530
Study 22994457 — intervention group
Group type: EXPERIMENTAL
Intervention: onQ, an interactive automated text‐messaging program
Number of subjects: 3530
Study 22994457 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of both QuitCoach and onQ
Number of subjects: 3530
Study 22994457 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice of either alone or the combined program
Number of subjects: 3530
Study 22994457 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention control
Number of subjects: 3530
Study 22994457 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention users
Number of subjects: 3530
Study 21657119 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive Outreach (AO)
Number of subjects: 83
Study 21657119 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 83
Study 19842940 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-guided dosing of coumarin derivatives
Number of subjects: 0
Study 19842940 — intervention group
Group type: COMPARATOR
Intervention: Standard dosing of coumarin derivatives (control group not explicitly mentioned)
Number of subjects: 0
Study 16751015 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg of Qbeta-Der p 1 intramuscularly
Number of subjects: 24
Study 16751015 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg of Qbeta-Der p 1 subcutaneously
Number of subjects: 24
Study 16751015 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg of Qbeta-Der p 1 intramuscularly
Number of subjects: 24
Study 16751015 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg of Qbeta-Der p 1 subcutaneously
Number of subjects: 24
Study 14501305 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term exercise program (50-70 minutes, 5 days per week, including aerobic activity, resistance training, and dynamic exercise)
Number of subjects: 0
Study 10972632 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan 80 mg once daily for 4 weeks, then titrated to 160 mg once daily for an additional 4 weeks
Number of subjects: 146
Study 10972632 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan
Number of subjects: 146
Study 10972632 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 146
Study 8829024 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine hydrochloride 200 mg once daily and nicardipine hydrochloride 20 mg three times daily (TID)
Number of subjects: 57
Study 8829024 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine hydrochloride 200 mg once daily
Number of subjects: 57
Study 8829024 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg once daily and nicardipine hydrochloride 20 mg TID
Number of subjects: 57
Study 8829024 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 81 mg once daily
Number of subjects: 57
Study 1578042 — intervention group
Group type: EXPERIMENTAL
Intervention: Subglottic secretion drainage (SSD) with HI-LO Evac tube
Number of subjects: 145
Study 1578042 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 145
Study 1578042 — intervention group
Group type: COMPARATOR
Intervention: Antacids
Number of subjects: 145
Study 2865028 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg betaxolol
Number of subjects: 5
Study 2865028 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg atenolol
Number of subjects: 5
Study 2865028 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg betaxolol
Number of subjects: 5
Study 2865028 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg propranolol
Number of subjects: 5
Study 2865028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 29625020 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal artery thermometry
Number of subjects: 68
Study 29625020 — intervention group
Group type: COMPARATOR
Intervention: Axillary thermometry
Number of subjects: 68
Study 27495093 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescuefix
Number of subjects: 44
Study 27495093 — intervention group
Group type: COMPARATOR
Intervention: Tape (Durapore)
Number of subjects: 44
Study 24093552 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (vitamins A, B-complex, C, E, and selenium)
Number of subjects: 423
Study 24093552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 423
Study 24093552 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation
Number of subjects: 423
Study 23149503 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow body implants (NBIs) with 2.2‐ or 2.4‐mm diameter
Number of subjects: 10
Study 20638454 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum-adjuvated split-virion vaccine (10 or 15 microg) in children aged 3-11 years
Number of subjects: 421
Study 20638454 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum-adjuvated split-virion vaccine (30 microg) in children aged 12-17 years
Number of subjects: 421
Study 20638454 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum-adjuvated whole-virion vaccine (5 microg) in children aged 12-17 years
Number of subjects: 421
Study 20638454 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum-adjuvated split-virion vaccine (5-30 microg) in children aged 12-17 years
Number of subjects: 421
Study 20638454 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum-adjuvated split-virion vaccine (5-15 microg) in children aged 3-11 years
Number of subjects: 421
Study 18339115 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (up to 200 mg daily in divided doses)
Number of subjects: 87
Study 18339115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 15814029 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine alone (25 mg/kg single dose)
Number of subjects: 78
Study 15814029 — intervention group
Group type: COMPARATOR
Intervention: Artesunate followed by mefloquine (4 mg/kg/day for 3 days followed by 15 mg/kg on day 3)
Number of subjects: 78
Study 12414332 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg, adjustable to 25 mg or 100 mg)
Number of subjects: 443
Study 12414332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 443
Study 12414332 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg, adjustable to 25 mg or 100 mg) and Placebo
Number of subjects: 443
Study 12580211 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 50
Study 12580211 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium
Number of subjects: 50
Study 12580211 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 50
Study 12580211 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 50
Study 12580211 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine
Number of subjects: 50
Study 8639079 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct laser photocoagulation
Number of subjects: 38
Study 8639079 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 38
Study 8639079 — intervention group
Group type: EXPERIMENTAL
Intervention: CSR eyes
Number of subjects: 38
Study 8639079 — intervention group
Group type: COMPARATOR
Intervention: Nonaffected fellow eyes
Number of subjects: 38
Study 1612530 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal salmon calcitonin (SCT) 100 IU daily plus calcium 500 mg daily
Number of subjects: 60
Study 1612530 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal salmon calcitonin (SCT) 100 IU daily for alternate cycles of 2 months with a 1‐month interval plus calcium 500 mg daily
Number of subjects: 60
Study 1612530 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal salmon calcitonin (SCT) 100 IU daily for alternate cycles of 3 months of treatment followed by a 3‐month interval plus calcium 500 mg daily
Number of subjects: 60
Study 1612530 — intervention group
Group type: COMPARATOR
Intervention: Calcium 500 mg daily alone (control group)
Number of subjects: 60
Study 1612530 — intervention group
Group type: COMPARATOR
Intervention: Proximal and distal forearm bone density (treated and control groups)
Number of subjects: 60
Study 6423316 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral disodium cromoglycate (DSCG) at a dose of 100 mg/kg/day in four divided doses for 6 months
Number of subjects: 1
Study 6423316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 30001288 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopic enema of 1 L polyethylene glycol (PEG)
Number of subjects: 131
Study 30001288 — intervention group
Group type: COMPARATOR
Intervention: Additional oral intake of 2 L polyethylene glycol (PEG)
Number of subjects: 131
Study 30001288 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopic enema of 1 L PEG
Number of subjects: 131
Study 30317015 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise programmes
Number of subjects: 44
Study 30317015 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-initiated training strategy
Number of subjects: 44
Study 30317015 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually supervised physiotherapy treatment
Number of subjects: 44
Study 27457916 — intervention group
Group type: EXPERIMENTAL
Intervention: Contract-relax stretching
Number of subjects: 84
Study 27457916 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 84
Study 27457916 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 84
Study 24388920 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenon E (800 mg epigallocatechin gallate)
Number of subjects: 98
Study 24388920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 24388920 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenon E
Number of subjects: 98
Study 22248928 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor stress test
Number of subjects: 80
Study 22248928 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 80
Study 22248928 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress-induced cortisol
Number of subjects: 80
Study 20036378 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusively human milk-based diet
Number of subjects: 207
Study 20036378 — intervention group
Group type: COMPARATOR
Intervention: Human milk and bovine milk-based products diet
Number of subjects: 207
Study 17033900 — intervention group
Group type: EXPERIMENTAL
Intervention: 75,000 SQ-T grass allergen tablets
Number of subjects: 855
Study 17033900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 855
Study 17033900 — intervention group
Group type: COMPARATOR
Intervention: Loratadine
Number of subjects: 855
Study 15652877 — intervention group
Group type: EXPERIMENTAL
Intervention: BPD subjects
Number of subjects: 30
Study 15652877 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 30
Study 11582601 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of HAART
Number of subjects: 4000
Study 11582601 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief that those taking HAART are 'no longer' or 'less' infective
Number of subjects: 4000
Study 11582601 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief that persons taking HAART are less infective
Number of subjects: 4000
Study 11582601 — intervention group
Group type: EXPERIMENTAL
Intervention: Not aware of HAART
Number of subjects: 4000
Study 9289913 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyvitamin pills 'Duovit'
Number of subjects: 0
Study 9289913 — intervention group
Group type: EXPERIMENTAL
Intervention: Premix 'Roche'
Number of subjects: 0
Study 9289913 — intervention group
Group type: COMPARATOR
Intervention: Supplement of third dishes with vitamin C
Number of subjects: 0
Study 8501579 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine 120 mg/m2 per day
Number of subjects: 34
Study 8501579 — intervention group
Group type: EXPERIMENTAL
Intervention: Didanosine 270 mg/m2 per day
Number of subjects: 34
Study 8501579 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 34
Study 2892517 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 5 micrograms/ml
Number of subjects: 40
Study 2892517 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 40
Study 2783184 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiprostil 800 micrograms (tablet and capsule)
Number of subjects: 10
Study 2783184 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiprostil 1200 micrograms (tablet and capsule)
Number of subjects: 10
Study 2783184 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiprostil (both doses and formulations)
Number of subjects: 10
Study 2783184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 4909818 — intervention group
Group type: EXPERIMENTAL
Intervention: Duogastrone capsules, one four times daily, half-an-hour before meals
Number of subjects: 14
Study 4909818 — intervention group
Group type: COMPARATOR
Intervention: Placebo containing magnesium trisilicate
Number of subjects: 14
Study 31958337 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (Lz) 2.5 mg/day
Number of subjects: 28
Study 31958337 — intervention group
Group type: COMPARATOR
Intervention: Testosterone (T) 1 mg/kg/month
Number of subjects: 28
Study 29761352 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual-reality simulator test for robotic surgical skills
Number of subjects: 32
Study 27922950 — intervention group
Group type: EXPERIMENTAL
Intervention: CIESI with targeted epidural catheter
Number of subjects: 76
Study 27922950 — intervention group
Group type: COMPARATOR
Intervention: Standard C7-T1 CIESI
Number of subjects: 76
Study 25727522 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle counselling intervention (diet, smoking cessation, and exercise)
Number of subjects: 500